ATE258057T1 - Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen - Google Patents

Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen

Info

Publication number
ATE258057T1
ATE258057T1 AT96942049T AT96942049T ATE258057T1 AT E258057 T1 ATE258057 T1 AT E258057T1 AT 96942049 T AT96942049 T AT 96942049T AT 96942049 T AT96942049 T AT 96942049T AT E258057 T1 ATE258057 T1 AT E258057T1
Authority
AT
Austria
Prior art keywords
treatment
therapeutic
diagnostic agents
microbial infections
infections
Prior art date
Application number
AT96942049T
Other languages
English (en)
Inventor
David Pascual
James Burritt
Don Burgess
Pati Glee
John Jutila
Mark Jutila
Robert Bargatze
Barry Pyle
Jim E Cutler
Yongmoon Han
Original Assignee
Univ Montana State
Ligocyte Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21726413&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE258057(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Montana State, Ligocyte Pharmaceuticals Inc filed Critical Univ Montana State
Application granted granted Critical
Publication of ATE258057T1 publication Critical patent/ATE258057T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT96942049T 1995-11-22 1996-11-21 Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen ATE258057T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US747795P 1995-11-22 1995-11-22
PCT/US1996/018796 WO1997018790A2 (en) 1995-11-22 1996-11-21 Therapeutic and diagnostic agents for the treatment of microbial infections

Publications (1)

Publication Number Publication Date
ATE258057T1 true ATE258057T1 (de) 2004-02-15

Family

ID=21726413

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96942049T ATE258057T1 (de) 1995-11-22 1996-11-21 Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen

Country Status (7)

Country Link
EP (1) EP0869801B1 (de)
JP (1) JP2000503630A (de)
AT (1) ATE258057T1 (de)
AU (1) AU1122697A (de)
CA (1) CA2238262A1 (de)
DE (1) DE69631381T2 (de)
WO (1) WO1997018790A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6204431B1 (en) 1994-03-09 2001-03-20 Abbott Laboratories Transgenic non-human mammals expressing heterologous glycosyltransferase DNA sequences produce oligosaccharides and glycoproteins in their milk
WO1998037915A1 (en) * 1997-02-26 1998-09-03 Hsc Research And Development Limited Partnership Antibiotic-ligand conjugates and methods of use thereof
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
GB9907429D0 (en) 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
CN1173706C (zh) 2001-02-28 2004-11-03 中国人民解放军第三军医大学 N-乙酰-d-氨基葡萄糖在制备治疗宫颈糜烂药物中的应用
CN1210038C (zh) 2003-03-27 2005-07-13 中国人民解放军第三军医大学 N－乙酰氨基葡萄糖在制备用于治疗毒物和药物中毒致脏器损伤的药物中的应用
CN1232257C (zh) 2003-03-27 2005-12-21 中国人民解放军第三军医大学 N－乙酰氨基葡萄糖在制备治疗和控制物理化学因素致非特异性炎症的药物中的应用
US7332179B2 (en) 2003-12-12 2008-02-19 Kimberly-Clark Worldwide, Inc. Tissue products comprising a cleansing composition
FR2876798A1 (fr) * 2004-10-14 2006-04-21 Univ Clermont Auvergne Diagnostic et traitement de la maladie de crohn
US7642395B2 (en) 2004-12-28 2010-01-05 Kimberly-Clark Worldwide, Inc. Composition and wipe for reducing viscosity of viscoelastic bodily fluids
FR2927171B1 (fr) * 2008-02-01 2010-03-19 Apoh Technollgies Sa Procede de detection et/ou de quantification et/ou d'identification in vitro de bacteries dans un materiau biologique
UA110325C2 (en) * 2009-07-03 2015-12-25 Australian Biomedical Company Pty Ltd Medicinal carbohydrates for treating respiratory conditions
AU2014233935A1 (en) 2013-03-21 2015-10-01 Caprion Proteomics Inc. Brucellosis, Q-Fever, and Lyme Disease biomarkers and uses thereof
CN112858675B (zh) * 2021-01-05 2022-03-29 杭州奥泰生物技术股份有限公司 一种新型冠状病毒抗原、抗体联合智能化检测装置
CN113884682B (zh) * 2021-04-30 2023-07-21 中国医学科学院血液病医院(中国医学科学院血液学研究所) 检测巨核细胞或血小板表面标志分子的产品在制备检测感染的产品中的用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470967A (en) * 1982-10-05 1984-09-11 Iowa State University Research Foundation Lectin-containing anti-viral vaccines for domestic animals and method of preparation
US5081034A (en) * 1988-11-14 1992-01-14 Brigham & Women's Hospital Cloned genes which encode elam-1
DK0745852T3 (da) * 1989-03-16 2002-10-14 Blood Res Center Anvendelse af funktionelle derivater af intercellulær adhæsion-molekylet ICAM-1 i antiviral terapi
ATE173827T1 (de) * 1990-08-02 1998-12-15 Antex Biolog Inc Adhäsionsrezeptoren für pathogene oder opportunistische mikroorganismen
WO1994005269A1 (en) * 1992-09-08 1994-03-17 Centocor, Inc. Peptide inhibitors of selectin binding

Also Published As

Publication number Publication date
DE69631381D1 (de) 2004-02-26
WO1997018790A3 (en) 1997-07-31
JP2000503630A (ja) 2000-03-28
WO1997018790A2 (en) 1997-05-29
CA2238262A1 (en) 1997-05-29
EP0869801B1 (de) 2004-01-21
AU1122697A (en) 1997-06-11
EP0869801A4 (de) 2001-01-17
EP0869801A2 (de) 1998-10-14
DE69631381T2 (de) 2004-10-21

Similar Documents

Publication Publication Date Title
ATE198050T1 (de) Therapeutische anwendungen von bpi-protein- produkten zur behandlung von humaner meningococcämia
HK1048831A1 (en) Human ctla-4 antibodies and their uses
ATE258057T1 (de) Therapeutische und diagnostische agenzien zur behandlung mikrobieller infektionen
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
DE69510940D1 (de) Pyrazolo und pyrrolopyridine
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
DE60137337D1 (de) Vorbeugende und therapeutsche monoklonale antikörper gegen vacciniavirusantigene
IL122248A (en) Use of nisin in the manufacture of a medicament for the treatment of an infection and pharmaceutical compositions comprising nisin for said treatment
DE69835536D1 (de) Zusammensetzungen zur behandlung von staphylococcus aureus infektionen
DE69530844D1 (de) Verfahren und substanzen gegen protozoen
ATE308328T1 (de) Pharmazeutische zusammensetzung enthaltend clindamycin und clotrimazol, zur behandlung vaginaler infektionen
DE69626816D1 (de) Verwendung von selegilin zur behandlung von gehörverlust bei säugetieren
ATE293994T1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
NO20005548L (no) Mykobakterieinhibitorer
DE69737088D1 (de) Therapeutisches agens zur behandlung von fiv infektionen
IT240104Y1 (it) Dispositivo per il trattamento del corpo umano.
TR199901385T2 (xx) Piperidin t�revleri.
DE3769497D1 (de) Mittel zur bekaempfung von phytopathogenen mikroben.
DE69130235T2 (de) Rezeptor-konjugate zum targeting von arzneiwirkstoffen und anderen wirksubstanzen
ATE212839T1 (de) Hämoregulatorische verbindungen
SE9902673D0 (sv) New composition
GEP20002177B (en) Ointment “Levaskani” for Treatment of Wounds and Burns
IT1318393B1 (it) Materiali proteici per la diagnosi, la profilassi e la terapiadell'infezione da citomegalovirus umano.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties